Article info
PDFOriginal research
Ethics and ego dissolution: the case of psilocybin
- Correspondence to Dr William R Smith, Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19083, USA; William.Smith{at}pennmedicine.upenn.edu
Citation
Ethics and ego dissolution: the case of psilocybin
Publication history
- Received January 14, 2020
- Revised March 12, 2020
- Accepted April 6, 2020
- First published May 27, 2020.
Online issue publication
November 29, 2021
Article Versions
- Previous version (27 May 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Psychedelic crossings: American mental health and LSD in the 1970s
- Research abuses against people of colour and other vulnerable groups in early psychedelic research
- Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
- Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement
- Chronic pain and psychedelics: a review and proposed mechanism of action
- PSYCHEDELIC DRUGS, MAGICAL THINKING AND PSYCHOSIS
- Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches
- Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?
- Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
- Open-label trial of anterior limb of internal capsule–nucleus accumbens deep brain stimulation for obsessive-compulsive disorder: insights gained